2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

155 This study showed a 24% relative risk reduction in the primary composite endpoint (fatal and nonfatal stroke and MI) (HR 0.76, 95% CI 0.62−0.93), and a marginally significant risk reduction in the recurrent stroke (HR 0.82, 95% CI 0.61−1.10) in favor of pioglitazone treatment. 155 In a meta-analysis of these three RCTs with a total of 4980 participants, pioglitazone significantly reduced the risk of recurrence stroke (HR 0.68, 95% CI 0.50−0.92) and three-point MACE (HR

also in 26,082 other papers

264 There is an increasing trend in emergency department visits for hypoglycemia in patients with type 2 diabetes in Taiwan from 2000 to 2010 (adjusted incidence rate ratio 4.88, 95% CI 3.94–6.05, p < 0.001). 265 From the data of the Taiwan NHIRD between 1998 and 2009, patients with symptomatic hypoglycemia were associated with hi

also in 63,971 other papers

36 This trial showed a trend of reduction in the risk of three-point MACE (HR 0.93, 95% CI 0.84−1.03) but a similar risk of ischemic stroke (HR 1.01, 95% CI 0.84−1.21) with dapagliflozin compared with placebo. 36 The subgroup analysis of patients with or without a history of stroke was not reported. 36 Four meta-analyses showe

also in 53,322 other papers